Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives $20.00 Consensus Target Price from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $20.00.

A number of brokerages recently weighed in on NBTX. TD Cowen assumed coverage on shares of Nanobiotix in a report on Friday, February 6th. They issued a “buy” rating for the company. Guggenheim upped their price objective on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd.

Nanobiotix Trading Up 1.5%

NBTX stock opened at $33.99 on Thursday. Nanobiotix has a 1 year low of $2.95 and a 1 year high of $37.11. The stock has a 50-day simple moving average of $23.90 and a 200-day simple moving average of $20.27.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in Nanobiotix during the fourth quarter worth about $390,000. Marshall Wace LLP bought a new position in Nanobiotix in the 4th quarter valued at about $220,000. Royal Bank of Canada increased its holdings in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Finally, Optiver Holding B.V. acquired a new position in shares of Nanobiotix in the 3rd quarter valued at approximately $101,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.